Business
Sandoz Bets on Biosimilars, Adding Up to 10 From Henlius in a $322M Deal
The world’s largest biosimilar maker will commercialize up to 10 Henlius-developed copies of blockbuster biologics globally, positioning for one of the industry’s biggest-ever patent cliffs.